BridgeMD
OPTIMISE: Optimized Immunosuppression for Corneal Transplantation: a multi-centre randomized controlled clinical trial
EU CTIS ID: 2022-500109-41-00
What this study is testing
To evaluate an evidence-based short- and long-term immunosuppressive protocol for DMEK that minimizes IOP elevation and endothelial cell loss.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients aged 21 years or older registered on the NOTR as candidates for DMEK corneal transplantation
You likely can't join if
- Inability to complete follow up or comply with study procedures
- Previous corneal graft in the study eye
- Known sensitivity or contraindication to the ingredients in the study medications
- History of uveitis or herpetic keratitis
- Human Leukocyte Antigen (HLA) typed allograft
- Pregnancy (current and planned) or lactation
See the full eligibility criteria
- Patients aged 21 years or older registered on the NOTR as candidates for DMEK corneal transplantation
- Inability to complete follow up or comply with study procedures
- Previous corneal graft in the study eye
- Known sensitivity or contraindication to the ingredients in the study medications
- History of uveitis or herpetic keratitis
- Human Leukocyte Antigen (HLA) typed allograft
- Pregnancy (current and planned) or lactation
- Use of other local or systemic immunosuppressive drugs
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.